• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Current therapy of the failing heart.

作者信息

Cohn J N

机构信息

Department of Medicine, University of Minnesota Medical School, Minneapolis 55455.

出版信息

Circulation. 1988 Nov;78(5 Pt 1):1099-107. doi: 10.1161/01.cir.78.5.1099.

DOI:10.1161/01.cir.78.5.1099
PMID:3052913
Abstract

Myocardial dysfunction eventuating in systolic and diastolic pump function abnormalities is a consequence of a wide variety of cardiac diseases. The symptoms that develop in this syndrome appear to be related as much to peripheral and neurohormonal mechanisms as to the underlying pathological and cardiac functional abnormality. Relief of symptoms, slowing of the progression of the cardiac functional abnormality, and prolongation of life provide the major agenda for the physician faced with the management of these patients. Judicious use of vasodilators, diuretics, digoxin, dietary therapy, and exercise therapy can relieve symptoms and improve the quality of life in most patients suffering from this syndrome. Recent evidence that vasodilator drugs can prolong life now provides the physician with further justification for routine use of this class of compounds. The eventual solution to the high mortality in this common disease process may be prevention of the development of overt heart failure by more prompt recognition and early treatment of the signs of ventricular dysfunction. This possibility must await the completion of current and proposed clinical trials.

摘要

相似文献

1
Current therapy of the failing heart.
Circulation. 1988 Nov;78(5 Pt 1):1099-107. doi: 10.1161/01.cir.78.5.1099.
2
Congestive heart failure: what should be the initial therapy and why?充血性心力衰竭:初始治疗应该是什么以及为什么?
Am J Cardiovasc Drugs. 2002;2(1):1-6. doi: 10.2165/00129784-200202010-00001.
3
Clinical aspects of left ventricular diastolic function assessed by Doppler echocardiography following acute myocardial infarction.急性心肌梗死后经多普勒超声心动图评估左心室舒张功能的临床方面
Dan Med Bull. 2001 Nov;48(4):199-210.
4
Medical therapy and prognosis in chronic heart failure. Lessons from clinical trials.慢性心力衰竭的药物治疗与预后。来自临床试验的经验教训。
Cardiol Clin. 1995 Feb;13(1):5-26.
5
Medical advances in the treatment of congestive heart failure.充血性心力衰竭治疗方面的医学进展。
Circulation. 1993 Dec;88(6):2941-52. doi: 10.1161/01.cir.88.6.2941.
6
Overview of the treatment of heart failure.心力衰竭的治疗概述。
Am J Cardiol. 1997 Dec 4;80(11A):2L-6L. doi: 10.1016/s0002-9149(97)00843-6.
7
Congestive heart failure.充血性心力衰竭
CMAJ. 1988 Apr 15;138(8):689-94.
8
Does cardiac resynchronisation therapy improve survival and quality of life in patients with end-stage heart failure?心脏再同步治疗能否改善终末期心力衰竭患者的生存率和生活质量?
Interact Cardiovasc Thorac Surg. 2008 Dec;7(6):1141-6. doi: 10.1510/icvts.2008.183707. Epub 2008 Jun 9.
9
Assessing the treatment of congestive heart failure: diuretics, vasodilators, and angiotensin-converting enzyme inhibitors.评估充血性心力衰竭的治疗:利尿剂、血管扩张剂和血管紧张素转换酶抑制剂。
Pharmacotherapy. 1993 Sep-Oct;13(5 Pt 2):82S-87S.
10
Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.第三次血管扩张剂-心力衰竭试验(V-HeFT III)的原理与设计:非洛地平作为依那普利和袢利尿剂的辅助治疗药物,用于慢性充血性心力衰竭患者,联合或不联合地高辛。V-HeFT III研究人员
Am J Cardiol. 1996 May 15;77(12):1078-82. doi: 10.1016/s0002-9149(96)00136-1.

引用本文的文献

1
Real-Time Remote Health-Monitoring Systems in a Medical Centre: A Review of the Provision of Healthcare Services-Based Body Sensor Information, Open Challenges and Methodological Aspects.医疗中心的实时远程健康监测系统:基于身体传感器信息的医疗服务提供、开放挑战和方法学方面的综述。
J Med Syst. 2018 Jul 25;42(9):164. doi: 10.1007/s10916-018-1006-6.
2
[Cost effectiveness of bisoprolol in heart failure. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study (CIBIS) for Germany].比索洛尔治疗心力衰竭的成本效益。德国心脏衰竭比索洛尔研究(CIBIS)的经济评估
Med Klin (Munich). 1997 Aug 15;92(8):499-504. doi: 10.1007/BF03044920.
3
Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure.
长期给予匹莫苯丹对中度充血性心力衰竭患者的临床疗效。
Heart Vessels. 1994;9(3):113-20. doi: 10.1007/BF01745236.
4
How do changes in lifestyle complement medical treatment in heart failure?生活方式的改变如何辅助心力衰竭的药物治疗?
Br Heart J. 1994 Sep;72(3 Suppl):S87-91. doi: 10.1136/hrt.72.3_suppl.s87.
5
Therapeutic management of dilated cardiomyopathy.扩张型心肌病的治疗管理
Cardiovasc Drugs Ther. 1994 Feb;8(1):83-8. doi: 10.1007/BF00877093.
6
Cardiovascular effects of alcohol.酒精对心血管的影响。
West J Med. 1989 Oct;151(4):430-9.
7
New drug approaches to the treatment of heart failure in infants and children.治疗婴幼儿心力衰竭的新药方法。
Drugs. 1990 Mar;39(3):388-93. doi: 10.2165/00003495-199039030-00005.
8
Left ventricular dilatation and failure post-myocardial infarction: pathophysiology and possible pharmacologic interventions.
Cardiovasc Drugs Ther. 1990 Oct;4(5):1363-74. doi: 10.1007/BF02018264.